- ￥318 - 5200
- MedChemExpress(MCE)
- 美国
- HY-10223
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1012054-59-9
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg/50 mg/100 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥770.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥318.0 |
| 规格： | 5 mg | 产品价格： | ￥700.0 |
| 规格： | 10 mg | 产品价格： | ￥890.0 |
| 规格： | 25 mg | 产品价格： | ￥1780.0 |
| 规格： | 50 mg | 产品价格： | ￥3200.0 |
| 规格： | 100 mg | 产品价格： | ￥5200.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
CUDC-101
CAS No. : 1012054-59-9
MCE 国际站：CUDC-101
产品活性：CUDC-101 是一种高效的 HDAC、EGFR 和 HER2 抑制剂，对应的 IC50 值分别为 4.4、2.4 和 15.7 nM。CUDC-101 是一种点击化学试剂。它含有 Alkyne 基团，可以和含有 Azide 基团的分子发生铜催化的叠氮-炔环加成反应 (CuAAc)。
研究领域：JAK/STAT Signaling | Protein Tyrosine Kinase/RTK | Cell Cycle/DNA Damage | Epigenetics
In Vitro: CUDC-101 inhibits both class I and class II HDACs, but not class III, Sir-type HDACs. CUDC-101 displays broad antiproliferative activity in many human cancer cell types. CUDC-101 is a potent and selective HDAC, EGFR, and HER2 inhibitor with only weak inhibition of the following protein kinases (IC50): KDR (VEGFR2) (849 nM), Src (11000 nM), Lyn (840 nM), Lck (5910 nM), Abl-1 (2890 nM), FGFR-2 (3430 nM), Flt-3 (1500 nM), and Ret (3200 nM).
CUDC-101 (300 nM) inhibits both the full length AR (flAR) and the AR variant AR-V7.
CUDC-101 is the most active agent in all three ATC cell lines screened for inhibitors of EGFR and HDACs, with half-maximal inhibitory concentration (IC50) at 0.15 μM for 8505c, and 1.66 μM for both C-643 and SW-1736 cells. CUDC-101 inhibits cancer cell migration and modulates epithelial-mesenchymal transition marker expression in ATC cells. CUDC-101 also inhibits HDAC and MAPK pathway, induces p21, and decreases survivin and XIAP expression in ATC cells.
CUDC-101 (1 μM) increases the acetylation of p53 and α-tubulin, nonhistone substrates of HDAC, in treated cancer cells. CUDC-101 modulates RTK activity and expression and exhibits immediate and stable inhibition of RTK and downstream Akt signaling.
In Vivo: CUDC-101 (120 mg/kg, iv, daily) induces tumor regression in the Hep-G2 liver cancer model and is more efficacious than erlotinib at its maximum tolerated dose (MTD). In the erlotinib-resistant A549 NSCLC xenograft model, CUDC-101 (120 mg/kg) shows potent inhibition of tumor growth. In the erlotinib-sensitive H358 NSCLC models, CUDC-101 (15, 30, 60 mg/kg, i.v.) inhibits tumor growth in a dose-dependent manner. CUDC-101 (120 mg/kg) causes significant tumor regression in the lapatinib-resistant, HER2-negative, EGFR-overexpressing MDA-MB-468 breast cancer model and the EGFR-overexpressing CAL-27 head and neck squamous cell carcinoma (HNSCC) model. CUDC-101 (120 mg/kg) also inhibits tumor growth in the K-ras mutant HCT116 colorectal and EGFR/HER2 (neu)-expressing HPAC pancreatic cancer models.
In an in vivo mouse model of metastatic ATC, CUDC-101 inhibits tumor growth and metastases, and significantly prolongs survival.
CUDC-101 (120 mg/kg) is effective against a broad range of tumor types in xenograft models.
相关产品：Covalent Screening Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | Immunology/Inflammation Compound Library | JAK/STAT Compound Library | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Covalent Screening Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Anti-Hepatitis C Virus Compound Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Prostate Cancer Compound Library | Osteogenesis Compound Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Cytokine Inhibitors Library | Osimertinib | Trichostatin A | Trastuzumab | Gefitinib | Cetuximab | Vorinostat | 4-Phenylbutyric acid | Erlotinib | Valproic acid | Afatinib | Sulforaphane | Panobinostat | Lapatinib | Entinostat | AG490 | Romidepsin | Trastuzumab deruxtecan | Genistein | Neratinib | Tucidinostat | Tucatinib | RGFP966 | Trastuzumab emtansine | Belinostat | AG-1478 | Ricolinostat | Pertuzumab
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验-101.8 60.1-61.7 10.8-11.4 27.3-28.7 豚鼠 cm 98.5-102.7 58.4-59.6 4.3-4.9 35.8-37.2
大气压 kPa 氧分压 kPa 英尺 米 0 0 101.31（760.0mmHg） 21.15(159.0mmHg) 10，000 3，048 69.51 (522.6mmHg) 14.55(109.4mmHg) 17，000 5，182 52.59(395.4mmHg) 11.01(82.8mmHg) 20，000 6，097 46.44(349.2mmHg) 9.72(73.1mmHg) 23，000
124 88 0.25 0.30 123 87 61 0.30 0.35 110 90 64 102 45 0.35 0.40 85 70 100 50 108 78 35 0.40 0.45 118 68 101 55 105 79 39 108 86 62
技术资料暂无技术资料 索取技术资料
